Microcap Ledger

Moves · $VEEA

Why did Veea (VEEA) stock go up? A Nasdaq governance fix

Veea closed up about 47% on 9 October 2026, the day after it said it had resolved its remaining Nasdaq governance deficiencies. What changed, and the financing behind it.

By Microcap Ledger desk · Published

The short version

  • Veea rose about 47% the day after it said it had fixed its remaining Nasdaq board and committee gaps.
  • That's the company's own statement; no Nasdaq letter confirming it had been disclosed. The bid-price issue was already cured in September.
  • Cash was $887,000 at 30 June. Its CEO's affiliate has lent about $3.4M since July, and a Roth ATM and a White Lion equity line are both in place.
Move, October 9, 2026
▲ +47.3%
$3.87 → $5.70 close
Volume
83.6M shares
~6× its 30-day average
Catalyst
Listing status
Market value at close
$354.62M
62.2M shares (as of 2026-08-10)
Cash, last filing
$1.94M
6 months to Jun 2026 · ~1 months at recent burn (estimate)
Listing
Nasdaq notice
8-K Item 3.01, 2026-06-04

Rankings #2 for September volume spike#3 for September volume increase#3 for October dollar volume (to date)

Likely catalyst: After Thursday's close, Veea said it had resolved its remaining Nasdaq board and committee deficiencies. Its bid-price deficiency was already cured in September.

Facts as of . Small caps move fast; check the latest filings.

What happened

Veea closed Friday at $5.70, up about 47% from Thursday’s $3.87. Roughly 84 million shares traded, against about 4.7 million on Thursday.

Friday’s volume was about six times the average of the previous 30 sessions. That average is inflated by earlier spikes, including about 200 million shares on 15 September. On a typical quiet day before the move, volume was well under a million shares.

The stock had already spiked once this week. It closed Monday at $5.72, up about 72%, then slid back to $3.87 by Thursday. Friday took it back to roughly where Monday ended.

The likely catalyst

At 5:22 p.m. ET on Thursday, Veea said it had fixed its remaining Nasdaq governance deficiencies. The gaps opened when independent director Douglas Maine died. Alan Black joined the compensation committee, Kanishka Roy joined the audit committee, and Helder Antunes left the board, which shrank to five members. Release.

This was not a new bid-price cure. Nasdaq had already confirmed in a 15 September letter that Veea met the $1 minimum bid. The governance fix is the company’s own statement. No Nasdaq letter confirming it had been disclosed by Friday’s close.

The timing makes this the most likely trigger. The release did not include new revenue, a signed merger or new financing. The NovaGen deal announced on 14 September is still a non-binding term sheet. 8-K.

Money and dilution check

At 30 June, Veea had $887,000 of cash plus $1.06 million of restricted cash that it can’t freely spend. It used $11.1 million in operations in the first half, on sales of $357,000. 10-Q.

Since then it has leaned on its CEO’s affiliate. NLabs, a principal shareholder, has lent about $3.4 million in unsecured demand loans since late July. They carry 10% interest and are due by 31 December. 29 September loans.

Two equity facilities were in place as of the cutoff:

  • ATM with Roth Capital Partners, LLC, signed 13 August. It allows up to $4.35 million of share sales at a 3% commission. Prospectus.
  • Equity line with White Lion Capital, dating from December 2024. Veea had drawn $904,000 through 30 June and sent another purchase notice on 5 August. 8-K.

No filing before Friday terminated either agreement. No filing shows whether Veea sold shares this week. That will show up in the next 10-Q.

Veea did a 1-for-20 reverse split, with split-adjusted trading from 31 August. Share counts filed before then need dividing by 20. 8-K.

See how ATM offerings work and equity lines.

How we measured: regular-session close to close, from Alpaca Markets (SIP) daily bars, split-adjusted. Volume is compared with the average of the 30 trading sessions before the move.

Does $VEEA spike often?

In the last 250 sessions, $VEEA closed up 20% or more on 5 days.

Oct 20, 2025Oct 16, 2026VolumeClose$15.40$1.56202M
DayClose changeVolume5 sessions later
Sep 14, 2026+46.8%28.8M+58.5%
Sep 15, 2026+149.3%202M−37.1%
Oct 1, 2026+59.9%80.6M+11.5%
Oct 5, 2026+71.8%66.9M−19.4%
Oct 9, 2026 (this move)+47.3%83.6M−26.1%

Regular-session closes. Highlighted bars are days up 20%+ close to close. "5 sessions later" is the close five trading days after, versus that day's close. History, not a forecast. Data: [source]

Dilution math

ATM sales agreement with Roth Capital Partners, LLC (13 Aug 2026): up to $4.35M. [source]

At the October 9, 2026 close of $5.70, that is about 764K new shares, or 1% of the 62.2M shares outstanding.

Arithmetic on filed capacity, not a forecast. Capacity isn't cash raised; sales show up in later filings. Separate from the White Lion equity line.

What to watch

  • 2026-12-31: About $3.4 million of NLabs demand loans fall due, unless repaid or called earlier. [source]
  • The September-quarter 10-Q, due in mid-November, should show any shares sold through the Roth ATM or the White Lion equity line after 30 June.
  • Whether Nasdaq confirms the governance cure in writing. The 8 October release is the company's own statement.
  • Any definitive agreement with NovaGen. None had been filed as of the cutoff.

Go deeper

Prices and volume: regular-session, previous-close data from [source].